Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

TerminatedOBSERVATIONAL
Enrollment

105

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 8, 2022

Study Completion Date

December 8, 2022

Conditions
Kidney InjuryKidney FailureKidney Failure, ChronicKidney Failure, AcuteKidney DiseasesKidney Transplant RejectionKidney Transplant InfectionKidney Transplant; ComplicationsKidney Disease, ChronicKidney Ischemia
Interventions
DIAGNOSTIC_TEST

AlloSure

AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.

DIAGNOSTIC_TEST

PAXGene

1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.

Trial Locations (1)

20037

George Washington University, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CareDx

INDUSTRY

collaborator

VirginiaBio Analytics, LLC

UNKNOWN

lead

George Washington University

OTHER

NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients | Biotech Hunter | Biotech Hunter